Patent details

LUC00360 Product Name: A gene therapy that expresses the human coagulation Factor IX variant R338L

Basic Information

Publication number:
LUC00360
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP212000053
Legal Status:
Withdrawn
Application number:
LUC00360
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/22/1715
Marketing Authorization Type:
Marketing Authorization Date:
23/02/2023
Marketing Authorization Status:
Claimed
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
28/10/2024
First Marketing Authorization date:
23/02/2023
Grant date:
Activation date:
Publication date:
04/11/2024
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
15/09/2034
SPC Extension Expiration:
15/09/2034
Rejection date:
Withdrawal date:
16/06/2025

Owner

From:
28/10/2024
 
 

Name:
uniQure biopharma B.V.
Address:
Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands (NL)

Agent

Name:
Dennemeyer & Associates S.A.
From:
28/10/2024
Address:
55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2024/14
Publication date:
06/12/2024
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
VRV
Bulletin edition number:
2025/08
Publication date:
03/07/2025
Description:
Section L: Applications for patents or supplementary protection certificates which have been withdrawn or are deemed to have been withdrawn (art. 32, 35.1, 39.5 of the law) Renunciation to a patent or supplementary protection certificate (Art. 72 of the law) Rejected applications for extensions for pediatric use of supplementary protections certificates